Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein

European Journal of Pharmacology

Volumn 578, Issue 2-3, 2008, Pages 148-158

  Zhu, Hao Jie ^a   Wang, Jun Sheng ^a,b   Donovan, Jennifer L ^a,b   Jiang, Yan ^b   Gibson, Bryan B ^a,b   DeVane, C Lindsay ^a,b   Markowitz, John S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Amphetamine; Atomoxetine; Methylphenidate; Modafinil; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMPHETAMINE; ATOMOXETINE; DOXORUBICIN; GLYCOPROTEIN P; METHYLPHENIDATE; MODAFINIL; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; VALSPODAR;

ANIMAL CELL; ARTICLE; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; CELL LINE; CELL STRAIN; DRUG ACCUMULATION; DRUG INHIBITION; DRUG TRANSPORT; ENZYME ASSAY; HUMAN; HUMAN CELL; HYPERACTIVITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; AMPHETAMINE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; BIOLOGICAL TRANSPORT; CENTRAL NERVOUS SYSTEM STIMULANTS; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ISOMERISM; LLC-PK1 CELLS; METHYLPHENIDATE; P-GLYCOPROTEIN; PROPYLAMINES; REPRODUCIBILITY OF RESULTS; RHODAMINE 123; SWINE; TRANSFECTION;

EID: 37349087428     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.09.035     Document Type: Article

References (45)

1. Alqawi O., Bates S., and Georges E. Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem. J. 382 (2004) 711-716
2. Angrist B., Corwin J., Bartlik B., and Cooper T. Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol. Psychiatry 22 (1987) 1357-1368
3. Beringer P.M., and Slaughter R.L. Transporters and their impact on drug disposition. Ann. Pharmacother. 39 (2005) 1097-1108
4. Bertelsen K.M., Greenblatt D.J., and von Moltke L.L. Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. Biopharm. Drug Dispos. 27 (2006) 219-227
5. Bosch T.M., Meijerman I., Beijnen J.H., and Schellens J.H. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45 (2006) 253-285
6. Boulton D.W., DeVane C.L., Liston H.L., and Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71 (2002) 163-169
7. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27 (2006) 17-24
8. Connor D.F., Ozbayrak K.R., Kusiak K.A., Caponi A.B., and Melloni Jr. R.H. Combined pharmacotherapy in children and adolescents in a residential treatment center. J. Am. Acad. Child Adolesc. Psych. 36 (1997) 248-254
9. Donovan J.L., Malcolm R.J., Markowitz J.S., and DeVane C.L. Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. Ther. Drug Monit. 25 (2003) 197-202
10. Faraone S.V., Biederman J., and Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J. Clin. Psychopharmacol. 22 (2002) 468-473
11. Greenhill L.L., Halperin J.M., and Abikoff H. Stimulant medications. J. Am. Acad. Child Adolesc. Psych. 38 (1999) 503-512
12. Greenhill L.L., Pliszka S., and Dulcan M.K. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psych. 41 (2002) 26S-49S (Suppl)
13. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., and Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3473-3478
14. James R.S., Sharp W.S., Bastain T.M., Lee P.P., Walter J.M., Czarnolewski M., and Castellanos F.X. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J. Am. Acad. Child Adolesc. Psych. 40 (2001) 1268-1276
15. Johnson L.V., Walsh M.L., and Chen L.B. Localization of mitochondria in living cells with rhodamine 123. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 990-994
16. Kratochvil C.J., Heiligenstein J.H., Dittmann R., Spencer T.J., Biederman J., Wernicke J., Newcorn J.H., Casat C., Milton D., and Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psych. 41 (2002) 776-784
17. Leonard B.E., McCartan D., White J., and King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum. Psychopharmacol. 19 (2004) 151-180
18. Markowitz J.S., and Patrick K.S. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin. Pharmacokinet. 40 (2001) 753-772
19. Markowitz J.S., Straughn A.B., and Patrick K.S. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 23 (2003) 1281-1299
20. Masereeuw R., Moons M.M., and Russel F.G. Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur. J. Pharmacol. 321 (1997) 315-323
21. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., and Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100 (1997) 2430-2436
22. Nakagami T., Yasui-Furukori N., Saito M., Tateishi T., and Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin. Pharmacol. Ther. 78 (2005) 43-51
23. Patrick K.S., and Markowitz J.S. Pharmacology of methylphenidate, amphetamine enatiomers and pemoline in attention-deficit hyperactivity disorder. Hum. Psychopharmacol. 12 (1998) 527-546
24. Pliszka S.R., Greenhill L.L., Crismon M.L., Sedillo A., Carlson C., Conners C.K., McCracken J.T., Swanson J.M., Hughes C.W., Llana M.E., Lopez M., and Toprac M.G. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psych. 39 (2000) 908-919
25. Robison L.M., Skaer T.L., Sclar D.A., and Galin R.S. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 16 (2002) 129-137
26. Safer D.J., Zito J.M., and DosReis S. Concomitant psychotropic medication for youths. Am. J. Psych. 160 (2003) 438-449
27. Sauer J.M., Ponsler G.D., Mattiuz E.L., Long A.J., Witcher J.W., Thomasson H.R., and Desante K.A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 31 (2003) 98-107
28. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., and Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
29. Schmitt U., Abou El-Ela A., Guo L.J., Glavinas H., Krajcsi P., Baron J.M., Tillmann C., Hiemke C., Langguth P., and Hartter S. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J. Neural. Transm. 113 (2006) 787-801
30. Spencer T., Biederman J., and Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr. Clin. North Am. 46 (1999) 915-927 vii
31. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10 (2003) 159-165
32. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54 (2003) 840-846
33. van Asperen J., Mayer U., van Tellingen O., and Beijnen J.H. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86 (1997) 881-884
34. van der Sandt I.C., Blom-Roosemalen M.C., de Boer A.G., and Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 11 (2000) 207-214
35. Wang J.S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., and DeVane C.L. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl). 173 (2004) 132-138
36. Wang J.S., Taylor R., Ruan Y., Donovan J.L., Markowitz J.S., and Lindsay De Vane C. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29 (2004) 551-557
37. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., and Devane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187 (2006) 415-423
38. Weiss M., and Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ 168 (2003) 715-722
39. Wilens T.E., and Biederman J. The stimulants. Psychiatr. Clin. North Am 15 (1992) 191-222
40. Wilens T.E., Spencer T., Biederman J., Wozniak J., and Connor D. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psych. 34 (1995) 110-112
41. Zhu H.J., Wang J.S., DeVane C.L., Williard R.L., Donovan J.L., Middaugh L.D., Gibson B.B., Patrick K.S., and Markowitz J.S. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine. Drug Metab. Dispos. 34 (2006) 1116-1121
42. Zhu H.J., Wang J.S., Donovan J.L., DeVane C.L., Gibson B.B., and Markowitz J.S. Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization. J. Chromatogr., B Analyt. Technol. Biomed. Life Sci. 846 (2007) 351-354
43. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., and DeVane C.L. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32 (2007) 757-764
44. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., Gefroh H.A., and Devane C.L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J. Pharmacol. Exp. Ther. 317 (2006) 850-857
45. Zito J.M., Safer D.J., dosReis S., Gardner J.F., Boles M., and Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283 (2000) 1025-1030